Qayed E. Optimizing care for gastric cancer with overt bleeding: Is systemic therapy a valid option? World J Clin Oncol 2025; 16(1): 100943 [DOI: 10.5306/wjco.v16.i1.100943]
Corresponding Author of This Article
Emad Qayed, MD, Associate Professor, Department of Medicine, Division of Digestive Diseases, Emory University School of Medicine, 49 Jesse Hill Junior Drive, Atlanta, GA 30303, United States. eqayed@emory.edu
Research Domain of This Article
Oncology
Article-Type of This Article
Editorial
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Oncol. Jan 24, 2025; 16(1): 100943 Published online Jan 24, 2025. doi: 10.5306/wjco.v16.i1.100943
Optimizing care for gastric cancer with overt bleeding: Is systemic therapy a valid option?
Emad Qayed
Emad Qayed, Department of Medicine, Division of Digestive Diseases, Emory University School of Medicine, Atlanta, GA 30303, United States
Author contributions: Qayed E designed the overall concept and outline of the manuscript and performed the writing and editing of the manuscript.
Conflict-of-interest statement: The author reports no conflict of interest.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Emad Qayed, MD, Associate Professor, Department of Medicine, Division of Digestive Diseases, Emory University School of Medicine, 49 Jesse Hill Junior Drive, Atlanta, GA 30303, United States. eqayed@emory.edu
Received: August 30, 2024 Revised: September 26, 2024 Accepted: October 22, 2024 Published online: January 24, 2025 Processing time: 60 Days and 15.8 Hours
Abstract
Gastric cancer (GC) and gastroesophageal junction cancer (GEJC) represent a significant burden globally, with complications such as overt bleeding (OB) further exacerbating patient outcomes. A recent study by Yao et al evaluated the effectiveness and safety of systematic treatment in GC/GEJC patients presenting with OB. Using propensity score matching, the study balanced the comparison groups to investigate overall survival and treatment-related adverse events. The study's findings emphasize that systematic therapy can be safe and effective and contribute to the ongoing debate about the management of advanced GC/GEJC with OB, highlighting the complexities of treatment decisions in these high-risk patients.
Core Tip: This editorial discusses a recent study addressing the management of gastric cancer (GC) patients with advanced GC and overt bleeding, focusing on survival outcomes and the safety of systematic therapies. The study underscores the importance of tailored treatment strategies in this high-risk patient population, providing evidence that while systematic therapy can be safe even in the presence of bleeding prior to systemic therapy. Bleeding after systemic therapy was linked to lower overall survival.
